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How effective are cognitive behavior therapies for major depression
and anxiety disorders? A meta-analytic update of the evidence
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We report the current best estimate of the effects of cognitive behavior therapy (CBT) in the treatment of major depression (MDD), generalized
anxiety disorder (GAD), panic disorder (PAD) and social anxiety disorder (SAD), taking into account publication bias, the quality of trials, and
the influence of waiting list control groups on the outcomes. In our meta-analyses, we included randomized trials comparing CBT with a
control condition (waiting list, care-as-usual or pill placebo) in the acute treatment of MDD, GAD, PAD or SAD, diagnosed on the basis of a
structured interview. We found that the overall effects in the 144 included trials (184 comparisons) for all four disorders were large, ranging
from g50.75 for MDD to g50.80 for GAD, g50.81 for PAD, and g50.88 for SAD. Publication bias mostly affected the outcomes of CBT in
GAD (adjusted g50.59) and MDD (adjusted g50.65), but not those in PAD and SAD. Only 17.4% of the included trials were considered to be
high-quality, and this mostly affected the outcomes for PAD (g50.61) and SAD (g50.76). More than 80% of trials in anxiety disorders used
waiting list control groups, and the few studies using other control groups pointed at much smaller effect sizes for CBT. We conclude that CBT
is probably effective in the treatment of MDD, GAD, PAD and SAD; that the effects are large when the control condition is waiting list, but
small to moderate when it is care-as-usual or pill placebo; and that, because of the small number of high-quality trials, these effects are still
uncertain and should be considered with caution.
Key words: Cognitive behavior therapy, major depression, generalized anxiety disorder, panic disorder, social anxiety disorder, meta-analysis,
publication bias, quality of trials, waiting list control groups
(World Psychiatry 2016;15:245–258)
Every year almost 20% of the general population suffers
from a common mental disorder, such as depression or an
anxiety disorder1. These conditions not only result in personal
suffering for patients and their families, but also in huge
economic costs, in terms of both work productivity loss and
health and social care expenditures2-6.
Several evidence-based treatments are available for com-
mon mental disorders, including pharmacological and psycho-
logical interventions. Many patients receive pharmacological
treatments, and these numbers are increasing in high-income
countries7. Psychological treatments are equally effective in the
treatment of depression8 and anxiety disorders9-11. However,
they are less available or accessible12, especially in low- and
middle-income countries. At the same time, about 75% of
patients prefer psychotherapy over the use of medication13.
The most extensively tested form of psychotherapy is cogni-
tive behavior therapy (CBT). Dozens of trials and several
meta-analyses have shown that CBT is effective in treating
depression8,14 and anxiety disorders9-11. However, in recent
years, it has become clear that the effects of CBT and other
psychotherapies have been considerably overestimated due to
at least three reasons.
The first reason is publication bias15,16. This refers to the ten-
dency of authors to submit, or journals to accept, manuscripts
for publication based on the direction or strength of the study’s
findings17. There is considerable indirect evidence of publica-
tion bias in psychotherapy research, based on excess publica-
tion of small studies with large effect sizes16. Moreover, there is
also direct evidence of publication bias: a recent study found
that almost one quarter of trials of psychotherapy for adult
depression funded by the US National Institutes of Health were
not published15. After adding the effect sizes of these unpub-
lished trials to those of the published ones, the mean effect size
for psychotherapy dropped by more than 25%.
The second reason why the effects of psychotherapies have
been overestimated is that the quality of many trials is sub-
optimal. In a meta-analysis of 115 trials of psychotherapy for
depression, only 11 met all basic indicators of quality, and the
effect sizes of these trials were considerably smaller than those
of lower quality ones18. However, that meta-analysis only
included trials up to 2008, and since then many new studies
have been conducted. Because more recent trials are typically
of a better quality than older ones, it is not known what the
current best estimate of the effect size of CBT is after taking
these newer studies into account.
A third reason why the effects of psychotherapy have been
overestimated is that many trials have used waiting list con-
trol groups. Although all control conditions in psychotherapy
trials have their own problems19,20, the improvement found
in patients on waiting lists has been found to be lower than
that expected on the basis of spontaneous remission19. It
has been suggested, therefore, that waiting list is in fact a
“nocebo” (the opposite of a placebo; an inert treatment that
appears to cause an adverse effect) and that trials using it
considerably overestimate the effects of psychological treat-
ments21. Other control conditions, such as care-as-usual and
pill placebo, can allow a better estimate of the true effect size
of CBT.
In the present paper, we report the most up-to-date and
accurate estimate of the effects of CBT in the treatment of
World Psychiatry 15:3 - October 2016 245
RESEARCH REPORT
major depression (MDD), generalized anxiety disorder (GAD),
panic disorder (PAD) and social anxiety disorder (SAD), taking
into account the three above-mentioned major problems of the
existing psychotherapy research: publication bias, low quality
of trials, and the nocebo effect of waiting list control groups.
METHODS
Identification and selection of studies
We searched four major bibliographic databases (PubMed,
PsycINFO, Embase and the Cochrane database of randomized
trials) by combining terms (both MeSH terms and text words)
indicative of psychological treatment and either SAD (social
phobia, social anxiety, public-speaking anxiety), GAD (worry,
generalized anxiety), or PAD with or without agoraphobia
(panic, panic disorder), with filters for randomized controlled
trials. We also checked the references of earlier meta-analyses
on psychological treatments for the included disorders. The
deadline for the searches was August 14, 2015.
For the identification of trials of CBT for MDD, we used an
existing database22 updated to January 2016 by combining
terms indicative of psychological treatment and depression
(both MeSH terms and text words).
We included randomized trials in which CBT was directly
compared with a control condition (waiting list, care-as-usual or
pill placebo) in adults with MDD, GAD, PAD or SAD. Only trials
in which recruited subjects met diagnostic criteria for the disor-
der according to a structured diagnostic interview – such as the
Structured Clinical Interview for DSM (SCID), the Composite
International Diagnostic Interview (CIDI) or the Mini Interna-
tional Neuropsychiatric Interview (MINI) – were included.
In addition to any therapy in which cognitive restructuring
was one of the core components, we also included purely
behavioral therapies, i.e., trials of behavioral activation for
depression and exposure for anxiety disorders. We included
therapies that used individual, group and guided self-help
formats, but excluded self-guided therapies without any pro-
fessional support, because their effects have been found to be
considerably smaller than other formats23. Studies on thera-
pies delivering only (applied) relaxation were excluded, as
were studies on eye movement desensitization and repro-
cessing (EMDR), interpersonal or psychodynamic therapy,
virtual reality therapy, transdiagnostic therapies, as well as
studies in which CBT was combined with pill placebo.
In order to keep heterogeneity as low as possible, we
included only studies using waiting list, care-as-usual or pill
placebo control groups. Care-as-usual was defined broadly as
anything patients would normally receive, as long as it was
not a structured type of psychotherapy. Psychological placebo
conditions were not included, because they have considerable
effects on depression24 and probably also on anxiety disor-
ders19. Comorbid mental or somatic disorders were not used
as an exclusion criterion. Studies on inpatients and on adoles-
cents or children (below 18 years of age) were excluded, as
were studies recruiting patients with other types of depressive
disorders than MDD (dysthymia or minor depression). We
also excluded maintenance studies, aimed at people who
already had a partial or complete remission after an earlier
treatment, and studies that did not report sufficient data to
calculate standardized effect sizes. Studies in English, German
and Dutch were considered for inclusion.
Quality assessment and data extraction
We assessed the quality of included studies using four criteria
of the “risk of bias” assessment tool developed by the Cochrane
Collaboration25. Although “risk of bias” and quality are not syn-
onyms25, the former can be seen as an indicator of the quality of
studies. The four criteria were: adequate generation of allocation
sequence; concealment of allocation to conditions; blinding of
assessors; and dealing with incomplete outcome data (this was
assessed as positive when intention-to-treat analyses were con-
ducted, meaning that all randomized patients were included in
the analyses). The assessment of the quality of included studies
was conducted by two independent researchers, and disagree-
ments were solved through discussion.
We also coded participant characteristics (disorder, recruit-
ment method, target group); characteristics of the psycho-
therapies (treatment format, number of sessions); and general
characteristics of the studies (country where the study was
conducted, year of publication).
Meta-analyses
For each comparison between a psychotherapy and a control
condition, the effect size indicating the difference between the
two groups at post-test was calculated (Hedges’ g). Effect sizes
of 0.8 can be assumed to be large, while effect sizes of 0.5 are
moderate, and effect sizes of 0.2 are small26. Effect sizes were
determined by subtracting (at post-test) the average score of
the psychotherapy group from the average score of the control
group, and dividing the result by the pooled standard deviation.
Because some studies had relatively small sample sizes, we
corrected the effect size for small sample bias27. If means and
standard deviations were not reported, we calculated the effect
size using dichotomous outcomes, and if these were not avail-
able either, we used other statistics (such a t or p value).
In order to calculate effect sizes, we used all measures
examining depressive symptoms, such as the Beck Depression
Inventory (BDI28 or BDI-II29) and the Hamilton Rating Scale
for Depression30, or anxiety symptoms, such as the Beck
Anxiety Inventory31, the Penn State Worry Questionnaire32, the
Fear Questionnaire33, and the Liebowitz Social Anxiety Scale34.
We did not use measures of mediators, dysfunctional thinking,
quality of life or generic severity. To calculate pooled mean
effect sizes, we used the Comprehensive Meta-Analysis (CMA)
246 World Psychiatry 15:3 - October 2016
software (version 3.3.070). Because we expected considerable
heterogeneity among the studies, we employed a random
effects pooling model in all analyses.
Numbers-needed-to-treat (NNT) were calculated using the
formulae provided by Furukawa35, in which the control group’s
event rate was set at a conservative 19% (based on the pooled
response rate of 50% reduction of symptoms across trials of
psychotherapy for depression)36. As a test of homogeneity of
effect sizes, we calculated the I2 statistic (a value of 0 indicates
no observed heterogeneity, and larger values indicate increas-
ing heterogeneity, with 25 as low, 50 as moderate, and 75 as
high heterogeneity)37. We calculated 95% confidence intervals
around I2 using the non-central chi-squared-based approach
within the Heterogi module for Stata38,39.
We conducted subgroup analyses according to the mixed
effects model, in which studies within subgroups are pooled
with the random effects model, while tests for significant
differences between subgroups are conducted with the fixed
effects model. For continuous variables, we used meta-
regression analyses to test whether there was a significant rela-
tionship between the continuous variable and the effect size,
as indicated by a Z value and an associated p value. Multivari-
ate meta-regression analyses, with the effect size as the depen-
dent variable, were conducted using CMA.
We tested for publication bias by inspecting the funnel plot
on primary outcome measures and by Duval and Tweedie’s trim
and fill procedure40, which yields an estimate of the effect size
after the publication bias has been taken into account. We also
conducted Egger’s test of the intercept to quantify the bias cap-
tured by the funnel plot and to test whether it was significant.
RESULTS
Selection and inclusion of trials
After examining a total of 26,775 abstracts (19,580 after
removal of duplicates), we retrieved 2,957 full-text papers for
further consideration. We excluded 2,813 of the retrieved
papers. The PRISMA flow chart describing the inclusion pro-
cess and the reasons for exclusion is presented in Figure 1.
A total of 144 trials met inclusion criteria for this meta-analysis:
54 on MDD, 24 on GAD, 30 on PAD, and 36 on SAD.
Characteristics of included trials
The 144 trials included a total of 184 comparisons between
CBT and a control condition (63 comparisons for MDD, 31 for
GAD, 42 for PAD, and 48 for SAD). A total of 11,030 patients
were enrolled (6,229 in the CBT groups, 2,469 in the waiting
list control groups, 1,823 in the care-as-usual groups and 509
in the pill placebo groups). A total of 113 trials were aimed at
adults in general and 31 at other more specific target groups.
Eighty trials recruited patients (also) from the community, 51
recruited exclusively from clinical populations, and 13 used
other recruitment methods. Sixty-seven trials were conducted
in North America, 14 in the UK, 36 in other European coun-
tries, 15 in Australia, 4 in East Asia, and 8 in other geographic
areas. Of all included trials, 44 (30.6%) were conducted in 2010
or later.
CBT was delivered in individual format in 87 comparisons,
in group format in 53, in guided self-help format in 35, and in
a mixed or another format in 9. The number of treatment ses-
sions ranged from one to 25.
Quality assessment
Sixty trials reported an adequate sequence generation,
while the other 84 did not. A total of 46 trials reported alloca-
tion to conditions by an independent (third) party. Seventy tri-
als reported blinding of outcome assessors and 57 conducted
intention-to-treat analyses. Only 25 trials (17.4%) met all four
quality criteria, 62 met two or three criteria, and the remaining
57 met one or none of the criteria. Of the trials conducted in
2010 or later, 29.5% were rated as high-quality, compared to
12.0% of the older studies.
Effects of CBT on MDD
The pooled effect size of the 63 comparisons between
CBT and control conditions in MDD41-94 was g50.75 (95% CI:
0.64-0.87), with high heterogeneity (I2571). This effect size
corresponds to a NNT of 3.86. Studies using a waiting list con-
trol group had significantly (p50.002) larger effect sizes
(g50.98; 95% CI: 0.80-1.17) than those using care-as-usual
(g50.60; 95% CI: 0.45-0.75) and pill placebo control groups
(g50.55; 95% CI: 0.28-0.81) (Table 1 and Figure 2).
Figure 1 Flow chart of inclusion of trials. MDD – major depression,
GAD – generalized anxiety disorder, PAD – panic disorder, SAD –
social anxiety disorder, CBT – cognitive behavior therapy
World Psychiatry 15:3 - October 2016 247
Only 11 of the 63 studies were rated as being high-quality.
The effect size in these studies was similar to that in the total
pool (g50.73; 95% CI: 0.46-1.00; I2578). No high-quality study
used a pill placebo control group. The difference between
waiting list and care-as-usual among the high-quality studies
was not significant (p50.06), but this may be related to the
small number of those studies.
Egger’s test indicated considerable asymmetry of the fun-
nel plot (intercept: 1.54; 95% CI: 0.59-2.50; p50.001). Duval
and Tweedie’s trim and fill procedure also indicated consider-
able publication bias (number of imputed studies: 8; adjusted
effect size: g50.65; 95% CI: 0.53-0.78; I2576). For high-quality
studies, no indication for publication bias was found (but this
may again be related to the small number of those studies).
Table 1 Effects of cognitive behavior therapy for major depression (MDD), generalized anxiety disorder (GAD), panic disorder (PAD)
and social anxiety disorder (SAD) compared to control conditions
N g 95% CI p I2 95% CI p NNT
MDD
All control conditions All studies 63 0.75 0.64-0.87 <0.001 71 62-77 3.86
High-quality studies 11 0.73 0.46-1.00 <0.001 78 56-86 3.98
Adjusted for publication bias 71 0.65 0.53-0.78 76 69-80 4.55
Type of control Waiting list 28 0.98 0.80-1.17 <0.001 68 50-77 0.002 2.85
Care-as-usual 30 0.60 0.45-0.75 <0.001 69 54-78 4.99
Pill placebo 5 0.55 0.28-0.81 <0.001 45 0-78 5.51
High-quality studies Waiting list 6 0.93 0.49-1.37 <0.001 82 56-90 0.06 3.02
Care-as-usual 5 0.43 0.16-0.70 0.002 46 0-79 7.29
GAD
All control conditions All studies 31 0.80 0.67-0.93 <0.001 33 0-56 3.58
High-quality studies 9 0.82 0.60-1.04 <0.001 46 0-73 3.49
Adjusted for publication bias 42 0.59 0.44-0.75 62 44-72 5.08
Type of control Waiting list 24 0.85 0.72-0.99 <0.001 13 0-47 <0.001 3.35
Care-as-usual 4 0.45 0.26-0.64 <0.001 0 0-68 6.93
Pill placebo 3 1.32 0.83-1.81 <0.001 0 0-73 2.08
High-quality studies Waiting list 8 0.88 0.67-1.10 <0.001 33 0-69 0.05 3.22
Care-as-usual 1 0.45 0.08-0.83 0.02 0 6.93
PAD
All control conditions All studies 42 0.81 0.59-1.04 <0.001 77 69-82 3.53
High-quality studies 4 0.61 0.27-0.96 0.001 26 0-75 4.89
Type of control Waiting list 33 0.96 0.70-1.23 <0.001 77 67-82 <0.001 2.92
Care-as-usual 4 0.27 20.12 to 0.65 0.17 31 0-77 12.25
Pill placebo 5 0.28 0.03-0.54 0.03 8 0-67 11.77
High-quality studies Waiting list 4 0.61 0.27-0.96 0.001 26 0-75 4.89
SAD
All control conditions All studies 48 0.88 0.74-1.03 <0.001 64 50-73 3.22
High-quality studies 8 0.76 0.47-1.06 <0.001 71 25-84 3.80
Type of control Waiting list 40 0.98 0.83-1.14 <0.001 64 47-73 <0.001 2.85
Care-as-usual 3 0.44 0.12-0.77 0.01 23 0-79 7.11
Pill placebo 5 0.47 0.24-0.70 <0.001 0 0-64 6.59
High-quality studies Waiting list 5 1.00 0.61-1.40 <0.001 71 0-87 0.03 2.79
Care as usual 2 0.30 20.04 to 0.64 0.08 0 10.91
Pill placebo 1 0.57 0.20-0.93 0.002 0 5.29
NNT – Number-needed-to-treat
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g 95% CI p g (95% CI)
Barnhofer et al41 0.91 0.15-1.67 0.02
Berger et al42 1.13 0.54-1.71 0.00
Burns et al43 0.95 0.20-1.71 0.01
Carrington44 1.60 0.63-2.58 0.00
Casanas et al45 0.29 0.03-0.55 0.03
Castonguay et al46 1.84 0.85-2.83 0.00
Choi et al47 0.89 0.38-1.40 0.00
Cooper et al48 0.43 0.02-0.85 0.04
00.010.3-16.018.1n49elluC
DeRubeis et al50 0.79 0.36-1.21 0.00
Dimidjian et al51, BA 0.81 0.32-1.30 0.00
Dimidjian et al51, CT 0.47 0.02-0.92 0.04
Duarte et al52 0.79 0.35-1.23 0.00
Elkin et al53 0.15 –0.20 to 0.51 0.40
Fann et al54, in-p 0.05 –0.50 to 0.59 0.87
Fann et al54 , tel 0.11 –0.32 to 0.54 0.63
Faramarzi et al55 1.72 1.13-2.31 0.00
Horrell et al56 0.51 0.31-0.71 0.00
Jamison & Scogin57 1.32 0.81-1.83 0.00
Jarrett et al58 0.63 0.16-1.10 0.01
Kanter et al59 0.61 –0.10 to 1.32 0.09
Kivi et al60 0.06 –0.42 to 0.54 0.80
Laidlaw et al61 0.40 –0.22 to 1.01 0.20
Larcombe & Wilson62 3.07 1.77-4.37 0.00
Lustman et al63 0.85 0.20-1.49 0.01
Martin et al64 1.68 0.99-2.36 0.00
Miranda et al65 0.16 –0.13 to 0.45 0.29
Mohr et al66 0.28 –0.16 to 0.71 0.21
Mohr et al67 0.52 0.03-1.00 0.04
Naeem et al68 1.12 0.81-1.43 0.00
O'Mahen et al69 0.61 0.08-1.15 0.03
Omidi et al70, CBT 1.63 1.05-2.21 0.00
Omidi et al70, MBCT 1.53 0.96-2.10 0.00
Pecheur & Edwards71, RCBT 1.93 0.72-3.14 0.00
Pecheur & Edwards71, SCBT 1.70 0.53-2.87 0.00
Perini et al72 0.61 0.00-1.22 0.05
00.097.2-55.171.2l73ateuiQ
Rahman et al74 0.62 0.48-0.77 0.00
Rizvi et al75 0.00 –0.69 to 0.69 1.00
Rohan et al56 0.99 0.25-1.73 0.01
Ross & Scott77 1.48 0.80-2.16 0.00
Safren et al78 0.72 0.13-1.32 0.02
Scott & Freeman79 0.25 –0.26 to 0.75 0.35
Scott et al80 0.46 –0.21 to 1.13 0.18
Smit et al81 0.04 –0.44 to 0.53 0.86
Songprakun & McCann82 0.60 0.06-1.14 0.03
Tandon et al83 0.33 –0.12 to 0.77 0.15
Teasdale et al84 1.46 0.56-2.37 0.00
Titov et al85 , iCBT (techn) 1.08 0.62-1.54 0.00
Titov et al85 , iCBT (clin) 1.07 0.62-1.52 0.00
Tovote et al86 , CBT 0.54 0.04-1.04 0.03
Tovote et al86 , MBCT 0.57 0.07-1.07 0.03
Turner et al87 0.10 –0.45 to 0.65 0.72
Vernmark et al88 , iCBT (e-mail) 0.93 0.39-1.46 0.00
Vernmark et al88 , iCBT (gsh) 0.56 0.03-1.08 0.04
Williams et al89 0.48 0.20-0.76 0.00 
Wollersheim & Wilson90, BIB 0.28 –0.65 to 1.21 0.56
Wollersheim & Wilson90, COP 0.15 –0.78 to 1.08 0.75
00.091.1-33.067.0g91noW
00.079.0-25.047.0g92noW
Wright et al93, CBT 1.19 0.43-1.95 0.00
Wright et al93, cCBT 1.28 0.51-2.05 0.00
85.0l94ateuZ –0.16 to 1.32 0.13
POOLED 0.75 0.64-0.87 0.00
0.20.10.0
Figure 2 Effects of cognitive behavior therapy (CBT) for major depression compared to control conditions: forest plot.
BA – behavioral activation, CT – cognitive therapy, in-p – in person, tel – telephone, MBCT – mindfulness based CBT, RCBT – religious CBT,
SCBT – secular CBT, iCBT – Internet-delivered CBT, techn – supported by a technician, clin – supported by a clinician, e-mail – supervised by
e-mail, gsh – guided self-help format, BIB – bibliotherapy, COP – coping, cCBT – computerized CBT
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Effects of CBT on GAD
The pooled effect size of the 31 comparisons between CBT and
control conditions in GAD95-117 was g50.80 (95% CI: 0.67-0.93;
NNT53.58), with low to moderate heterogeneity (I2533) (Table 1
and Figure 3). The vast majority of studies (24 of 31) used a waiting
list control group. Studies using a pill placebo control group
(g51.32) had a significantly (p<0.001) larger effect than those using
a waiting list (g50.85) or care-as-usual control group (g50.45). The
number of studies using pill placebo (N53) and care-as-usual con-
trol groups (N54) was very small, however (Table 1 and Figure 3).
Only 9 of the 31 studies were rated as high-quality, and 8 of
these used a waiting list control group, so the effects of care-
as-usual and pill placebo among high-quality studies could
not be estimated.
Egger’s test was significant (intercept: 1.60; 95% CI: 0.38-
2.83; p50.006). Duval and Tweedie’s trim and fill procedure
resulted in an adjusted effect size of g50.59 (95% CI: 0.44-0.75;
I2562; number of imputed studies: 11). For high-quality stud-
ies, no indication for publication bias was found (but this may
again be related to the small number of those studies).
Effects of CBT on PAD
The 42 comparisons between CBT and control conditions
in PAD118-147 resulted in a pooled effect size of g50.81 (95%
CI: 0.59-1.04; I2577; NNT53.53). In the vast majority of the
comparisons (N533), a waiting list control condition was
used. The difference between studies using a waiting list
(g50.96) and either care-as-usual (g50.27) or pill placebo
(g50.28) was significant (p<0.001). The four comparisons of
CBT versus care-as-usual even indicated a non-significant
effect size (g50.27; 95% CI: 20.12 to 0.65; p50.17) (Table 1 and
Figure 4).
The four high-quality studies all used a waiting list control
group and resulted in an effect size of g50.61 (95% CI: 0.27-
0.96).
Although Egger’s test indicated significant asymmetry of the
funnel plot (intercept: 3.62; 95% CI: 0.90-6.34; p50.005), Duval
and Tweedie’s trim and fill procedure did not indicate any
missing studies and therefore the adjusted and unadjusted
effect sizes were the same. In the four high-quality studies, no
indication for publication bias was found.
g 95% CI p g (95% CI)
Andersson et al95 0.37 –0.14 to 0.89 0.16
Bakhshani et al96 1.08 –0.02 to 2.18 0.05
Barlow et al97 , CBT 1.07 0.20-1.94 0.02
Barlow et al97, CBT + RELAX 0.71 –0.15 to 1.57 0.11
Butler et al98, CBT 1.07 0.40-1.74 0.00
Butler et al98, BT 0.44 –0.20 to 1.08 0.18
Dugas et al99 0.86 0.24-1.48 0.01
Dugas et al100 1.11 0.53-1.68 0.00
Hoyer et al101, WO 0.77 0.22-1.32 0.01
Ladouceur et al102 1.39 0.54-2.24 0.00
Linden et al103 0.49 0.03-0.96 0.04
Mohlman et al104, CBT 0.47 –0.37 to 1.31 0.28
Mohlman et al104 , EN CBT 0.62 –0.38 to 1.61 0.23
Paxling et al105 1.13 0.67-1.60 0.00
Power et al106 1.40 0.48-2.33 0.00
Power et al107 1.37 0.69-2.05 0.00
Robinson et al108 , iCBT (techn) 1.16 0.73-1.58 0.00
Robinson et al108 , iCBT (clin) 1.13 0.70-1.55 0.00
Stanley et al109 0.90 –0.35 to 2.14 0.16
Stanley et al110 0.45 0.08-0.83 0.02
Stanley et al111, clin supp 0.49 0.16-0.82 0.00
Stanley et al111, lay 0.37 0.05-0.70 0.02
Titov et al112 1.08 0.46-1.69 0.00
Treanor et al113 1.77 0.95-2.58 0.00
Van der Heiden et al114 , MCT 0.78 0.26-1.31 0.00
Van der Heiden et al114 0.50 –0.02 to 1.02 0.06
Wetherell et al115 0.85 0.20-1.49 0.01
White et al116, CT 0.59 –0.10 to 1.28 0.09
White et al116, BT 0.56 –0.12 to 1.25 0.11
White et al116 0.55 –0.15 to 1.25 0.12
Zinbarg et al117 1.36 0.34-2.38 0.01
POOLED 0.80 0.67-0.93 0.00
0.0 1.0 2.0
, IUT
, CBT
Figure 3 Effects of cognitive behavior therapy (CBT) for generalized anxiety disorder compared to control conditions: forest plot.
RELAX – relaxation, BT – behavior therapy, WO – worry exposure, EN CBT – enhanced CBT, iCBT – Internet-delivered CBT, techn – techni-
cian assistance, clin – clinician assistance, clin supp – supported by a clinician, lay – lay provider, MCT – metacognitive therapy, IUT –
intolerance-of-uncertainty therapy, CT – cognitive therapy
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Effects of CBT on SAD
The 48 comparisons between CBT and a control condition148-
183 resulted in a pooled effect size of g50.88 (95% CI: 0.74-1.03;
I2564; NNT53.22). Again, the large majority of studies used a
waiting list control group (N540), with only three using care-as-
usual and five pill placebo. The studies using a waiting list con-
trol group resulted in significantly (p<0.001) larger effect sizes
(g50.98) than those using a pill placebo (g50.47) or care-as-
usual control group (g50.44) (Table 1 and Figure 5).
Only eight studies were rated as high-quality, and five of
these used a waiting list control group. This implies that for
SAD there are not enough high-quality studies to assess the
effects of CBT compared to care-as-usual or pill placebo.
Egger’s test pointed at significant asymmetry of the funnel
plot (intercept: 2.46; 95% CI: 0.96-3.96; p50.001), but Duval
and Tweedie’s trim and fill procedure did not indicate missing
studies and the adjusted and unadjusted effect sizes were the
same.
Multivariate meta-regression analyses
We conducted four separate analyses, for each disorder, with
the effect size as the dependent variable and characteristics of
g 95% CI p g (95% CI)
–0.12 –0.56 to 0.32 0.60
–0.10 –0.58 to 0.38 0.67
0.42 –0.33 to 1.17 0.27
0.49 –0.25 to 1.23 0.19
0.42 –0.04 to 0.88 0.07
0.18 –0.39 to 0.74 0.53
1.53 0.64-2.43 0.00
0.54 –0.07 to 1.15 0.08
0.86 0.33-1.40 0.00
1.64 0.72-2.55 0.00
2.20 1.55-2.85 0.00
2.72 1.76-3.68 0.00
1.73 0.85-2.60 0.00
2.05 1.13-2.97 0.00
0.22 –0.64 to 1.07 0.62
–0.46 –1.34 to 0.42 0.31
–0.37 –1.17 to 0.42 0.36
0.78 0.22-1.34 0.01
1.14 0.55-1.72 0.00
0.98 0.23-1.73 0.01
2.07 1.24-2.90 0.00
2.01 1.20-2.82 0.00
2.05 1.24-2.86 0.00
0.71 –0.14 to 1.56 0.10
0.63 –0.17 to 1.43 0.12
0.46 –0.25 to 1.17 0.21
0.43 –0.24 to 1.10 0.21
0.61 –0.26 to 1.48 0.17
0.05 –0.79 to 0.89 0.91
–0.07 –0.88 to 0.73 0.86
1.60 0.75-2.45 0.00
1.60 0.73-2.47 0.00
1.94 1.24-2.65 0.00
0.51 –0.04 to 1.06 0.07
0.25 –0.38 to 0.89 0.43
0.61 0.00-1.22 0.05
1.01 0.37-1.65 0.00
0.93 0.43-1.44 0.00
–0.37 –1.23 to 0.48 0.39
0.42 –0.46 to 1.29 0.35
0.78 –0.12 to 1.67 0.09
0.20 –0.34 to 0.74 0.46
0.81 0.59-1.04 0.00
–1.0       0.0        1.0
Addis et al118
Bakker et al119
Barlow et al120 , CT
Barlow et al120 , CT+RELAX 
Barlow et al121
Black et al122
Botella et al123 
Carlbring et al124
Carlbring et al125
Carter et al126 
Casey et al127
Clark et al128 
Clark et al129 , BCBT
Clark et al129 , FCBT
Gould et al129 , BIB
Gould et al130, GIC
Gould et al131
Hazen et al132, BIB (gsh)
Hazen et al132 
Hendriks et al133
Ito et al134 , EXT+INT
Ito et al134 , EXT
Ito et al134 , INT
Klein & Richards135
Klosko et al136
Lessard et al137, CBT
Lessard et al137, PM
Lidren et al138, BT (in-p)
Lidren et al138, BT (gsh)
Ross & Scott139
Schmidt et al140, CBT
Schmidt et al140, CBT+RESP
Schmidt et al141 
Sharp et al142
Sharp et al143, CBT (grp)
Sharp et al143, CBT (ind)
Swinson et al144 
Telch et al145
Williams et al146 , CT
Williams et al146 , CT+EXP
Williams et al146, EXP
Wims et al147
POOLED
, BIB (gsh)
Figure 4 Effects of cognitive behavior therapy (CBT) for panic disorder compared to control conditions: forest plot.
CT – cognitive therapy, RELAX – relaxation, BCBT – brief CBT, FCBT – full CBT, BIB – bibliotherapy, GIC – guided imaginal coping, gsh –
guided self help, grp – group format, EXT – external cues, INT – interoceptive, PM – panic management, in-p – in person, RESP – respiratory
training, ind – individual format, EXP – exposure
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the participants (adults in general or more specific popu-
lations), the intervention (format and number of sessions) and
the study in general (type of control group, quality and geo-
graphic area) as predictors. As shown in Table 2, very few pre-
dictors were significant in these analyses, possibly because of
the relatively small number of studies per disorder and the rela-
tively large number of predictors.
DISCUSSION
In this study, we aimed to establish the most up-to-date
and accurate estimate of the effects of CBT in the treatment of
MDD, GAD, PAD and SAD. We also aimed to examine whether
the problems of publication bias, low quality of trials, and the
use of waiting list control groups have an impact on the effect
g 95% CI p g (95% CI)
Abramowitz et al148 0.64 –0.22 to 1.49 0.15
Andersson et al149 0.71 0.21-1.21 0.01
Beidel et al150 , EXP+SOC 3.42 2.48-4.36 0.00
Beidel et al150, EXP 2.05 1.36-2.75 0.00
Berger et al151 0.75 0.18-1.31 0.01
Blanco et al152 0.26 –0.24 to 0.76 0.31
Botella et al153 1.21 0.59-1.83 0.00
Carlbring et al154 1.07 0.52-1.62 0.00
Clark et al155 , CT 2.26 1.49-3.02 0.00
Clark et al155 , EXP+RELAX 0.94 0.31-1.57 0.00
Craske et al156 0.84 0.31-1.38 0.00
Davidson et al157 0.57 0.20-0.93 0.00
Furmark et al158 0.64 0.20-1.09 0.00
Goldin et al159 0.45 0.00-0.91 0.05
Gruber et al160 , CBT 0.69 0.00-1.39 0.05
Gruber et al 160, CBT 1.15 0.40-1.89 0.00
Heimberg et al161 0.47 –0.08 to 1.01 0.09
Himle et al162 0.78 0.25-1.30 0.00
Hofmann163, CBT 0.81 0.26-1.36 0.00
Hofmann163 , EXP 0.50 –0.03 to 1.03 0.07
Hope et al164 , CBT 0.75 –0.08 to 1.58 0.08
Hope et al164, EXP 1.45 0.49-2.41 0.00
Kocovski et al165,CBT 0.79 0.33-1.24 0.00
Kocovski et al165, MAGT 0.74 0.29-1.20 0.00
Ledley et al166 1.58 0.80-2.35 0.00
Leichsenring et al167 0.87 0.60-1.14 0.00
Mattick et al168, CR 0.66 –0.20 to 1.51 0.13
Mattick et al168, EXP 0.97 0.08-1.86 0.03
Mattick et al168 , CR+EXP 1.13 0.22-2.05 0.02
Mörtberg et al169, CT 0.41 –0.08 to 0.90 0.10
Mörtberg et al169 , IGCT 0.19 –0.28 to 0.67 0.42
Mulkens et al170 1.00 0.20-1.80 0.01
Newman et al171 0.65 –0.04 to 1.34 0.06
Oosterbaan et al172 0.34 –0.26 to 0.93 0.27
Pishyar et al173 4.37 3.01-5.72 0.00
Price et al174 0.83 0.26-1.40 0.00
Rapee et al175, gsh 0.75 0.01-1.48 0.05
Rapee et al175 , gsh+5 sessions 0.84 0.12-1.56 0.02
Robillard et al176 1.01 0.28-1.74 0.01
Salaberria et al177, EXP 1.25 0.47-2.02 0.00
Salaberria et al177, CT+EXP 1.15 0.32-1.97 0.01
Stangier et al178, CBT (ind) 0.37 –0.22 to 0.97 0.22
Stangier et al178, CBT (grp) 0.04 –0.55 to 0.62 0.90
Stangier et al179 0.75 0.30-1.21 0.00
Titov et al180 0.94 0.53-1.35 0.00
Titov et al181 1.18 0.71-1.65 0.00
Titov et al182 1.01 0.50-1.52 0.00
Turner et al183 0.74 –0.03 to 1.52 0.06
POOLED 0.88 0.74-1.03 0.00
0.0         1.0        2.0
Figure 5 Effects of cognitive behavior therapy (CBT) for social anxiety disorder compared to control conditions: forest plot.
EXP – exposure, SOC – social skills, CT – cognitive therapy, RELAX – relaxation, cCBT – computerized CBT, MAGT – mindfulness acceptance
group therapy, CR – cognitive restructuring, IGCT – intensive group CT, gsh – guided self help, ind – individual format, grp – group format
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sizes. We found that the overall effects for all four disorders
were large, ranging from g50.75 for MDD to g50.80 for GAD,
g50.81 for PAD, and g50.88 for SAD.
The first problem, publication bias, mostly affected the out-
comes of CBT for GAD and MDD. For GAD, it was estimated
that about one quarter of the studies were missing and, after
adjusting for these missing studies, the effect size dropped
from g50.80 to g50.59. For MDD, 14% of the studies were
missing, and the pooled effect size dropped from g50.75 to
g50.65. However, this was a relatively small drop compared to
that reported in other studies on publication bias in psycho-
therapies for MDD15,18,184. This may be due to the fact that we
used more stringent inclusion criteria for this meta-analysis
(only patients meeting diagnostic criteria for MDD; only wait-
ing list, treatment-as-usual or pill placebo control groups; only
CBT). In PAD and SAD, we found few indications of publica-
tion bias.
The second problem we aimed to examine was the quality
of trials. We found that the methodological quality in most
studies was low or unknown. We evaluated the quality by the
Cochrane “risk of bias” assessment tool, and found that across
all disorders only 25 trials (17.4%) were rated as high-quality.
The effect size was lower in high-quality studies for PAD
(g50.61 compared to g50.81 in all studies) and SAD (g50.76
compared to g50.88 in all studies). We did not find strong indi-
cations that the quality of trials was associated with the effect
size in MDD and GAD. Although we did not find a strong asso-
ciation between effect size and quality of trials for all disorders,
the small number of high-quality studies still means that the
overall effect sizes we found for all four disorders are uncertain.
The third problem we aimed to examine was the influence
of waiting list control groups on the effects of CBT. We found
that the vast majority of studies for the three anxiety disorders
used a waiting list control group (77.4% of the comparisons for
GAD, 78.6% for PAD, and 83.3% for SAD). In MDD, the number
of studies using care-as-usual and pill placebo control condi-
tions was larger, but still 44.4% (28 out of 63) of the included
studies used a waiting list control group. This means that
much of the evidence on the effects of CBT is based on the use
of waiting list control groups. As indicated earlier, improvements
found in patients on waiting lists are lower than can be expected
on the basis of spontaneous remission19,185. Waiting list is prob-
ably a “nocebo”21, considerably overestimating the effects of
psychological treatments. This was confirmed in our meta-
analysis, in which we found for each of the disorders that studies
with a waiting list control group resulted in significantly higher
effect sizes than those with a care-as-usual or pill placebo con-
trol group.
The few studies on anxiety disorders that used care-as-usual
or pill placebo control groups indicated small to moderate
Table 2 Standardized regression coefficients of characteristics of studies on cognitive behavior therapy for major depression (MDD),
generalized anxiety disorder (GAD), panic disorder (PAD) and social anxiety disorder (SAD) compared to control conditions
MDD GAD PAD SAD
Coeff SE p Coeff SE p Coeff SE p Coeff SE p
Quality of trial 20.05 0.07 0.46 20.01 0.07 0.94 20.09 0.11 0.43 20.01 0.09 0.92
Control condition Waiting list Ref. Ref. Ref. Ref.
Care-as-usual 20.43 0.15 0.01 20.30 0.38 0.43 20.61 0.41 0.69 20.67 0.46 0.15
Pill placebo 20.44 0.30 0.15 0.60 0.40 0.15 20.67 0.34 0.05 20.53 0.29 0.08
Adults vs. specific target groups 0.01 0.17 0.95 20.43 0.28 0.14 20.07 0.38 0.85 0.67 0.75 0.38
Format Individual Ref. Ref. Ref. Ref.
Group 20.23 0.21 0.28 20.17 0.23 0.47 0.28 0.31 0.37 20.06 0.25 0.83
Guided self-help 20.32 0.23 0.16 0.06 0.28 0.84 20.36 0.30 0.24 20.06 0.36 0.86
Mixed/other 20.28 0.28 0.32 0.04 0.30 0.89 0.48 0.68 0.48 0.20 0.45 0.65
Number of sessions 20.01 0.02 0.67 20.01 0.02 0.60 0.06 0.04 0.13 0.04 0.03 0.19
Geographic area North America Ref. Ref. Ref. Ref.
Europe 20.02 0.19 0.92 20.51 0.19 0.01 0.65 0.25 0.01 20.13 0.24 0.59
Australia 0.31 0.29 0.29 20.19 0.30 0.52 0.37 0.54 0.49 0.40 0.31 0.20
Other 0.47 0.22 0.04 20.78 0.66 0.25 1.58 0.48 0.003
Significant p values are highlighted in bold prints
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effect sizes. In the four studies comparing CBT for PAD with
care-as-usual, the effect size was even non-significant (p50.17).
Furthermore, because of the small number of studies, and the
even smaller number of high-quality studies, the effects of CBT
in anxiety disorders are quite uncertain.
An exception to the small to moderate effects of CBT in anx-
iety disorders was the group of studies comparing CBT to pill
placebo for GAD. These studies resulted in a very large effect
size (g51.32). However, because of the small number of trials
and the low quality of all three of them, these results should be
considered with caution.
One reason to conduct this meta-analysis was to examine
whether the quality of trials has increased in recent years.
Indeed, 29.5% of the studies conducted in 2010 or later were
rated as high-quality, while that was true for only 12.0% of the
older studies. Furthermore, 52.0% of all high-quality studies
were conducted in 2010 or later. This is likely to have led to a
more accurate estimate of effect sizes.
The present study has several strengths, including the broad
scope of the meta-analyses, covering four common mental
disorders, the rigorous selection and assessment of the trials,
and their relatively large number.
One possible limitation is that we used strict inclusion crite-
ria, only focusing on trials in which patients met diagnostic
criteria for the disorder according to a structured interview
and trials in which either a waiting list, care-as-usual or pill
placebo control group was used. We did not include studies in
which, for example, generic counselling was used as a control
condition. This may contribute to explain the small number
of trials comparing CBT with control conditions other than
waiting lists, especially in anxiety disorders and among the
sets of high-quality studies. Furthermore, care-as-usual control
groups can vary considerably depending on the country and
the treatment setting where the therapy is offered, and may
therefore be too heterogeneous to allow a reliable assessment of
the effects across studies. Finally, we only focused on short-
term outcomes, because only few studies reported long-term
outcomes and the follow-up periods differed considerably.
On the basis of our data, we conclude that CBT is probably
effective in the treatment of MDD, GAD, PAD and SAD, and
that the effects are large when compared to waiting list control
groups, but small to moderate when compared to more con-
servative control groups, such as care-as-usual and pill place-
bo. Because of the small number of high-quality studies, these
effects are still uncertain and should be considered with
caution.
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